Observational Study for Lung Cancer Patients Treated With Nivolumab

A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus

NCT05034926 ·Status: COMPLETED

Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer

NCT03433534 ·Status: COMPLETED

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

NCT04263051 ·Status: COMPLETED ·Phase: PHASE2

Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy

NCT02910999 ·Status: COMPLETED

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

NCT01721759 ·Status: COMPLETED ·Phase: PHASE2

A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab

NCT03804554 ·Status: COMPLETED

An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC

NCT02409368 ·Status: COMPLETED ·Phase: PHASE2

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT05500092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient

NCT03132493 ·Status: COMPLETED

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

NCT02259621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

NCT03262779 ·Status: COMPLETED ·Phase: PHASE2

Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients

NCT03509584 ·Status: TERMINATED ·Phase: PHASE1

Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

NCT03469960 ·Status: COMPLETED ·Phase: PHASE3

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

NCT02950038 ·Status: WITHDRAWN ·Phase: PHASE2

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

NCT03564197 ·Status: COMPLETED ·Phase: NA

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

NCT02869789 ·Status: COMPLETED ·Phase: PHASE4

An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice

NCT01893268 ·Status: COMPLETED

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

NCT03090737 ·Status: COMPLETED ·Phase: PHASE2

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

NCT03575793 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

NCT06169956 ·Status: RECRUITING

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma

NCT02434081 ·Status: COMPLETED ·Phase: PHASE2

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

NCT03774732 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer

NCT02551211 ·Status: TERMINATED ·Phase: NA

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

NCT03770299 ·Status: WITHDRAWN ·Phase: PHASE2

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

NCT07024862 ·Status: ACTIVE_NOT_RECRUITING